Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11192594 | 0.85 | CA2 (0.53) | CA2CYP1A2CYP3A4CYP2D6ATM | |
| SCHEMBL2420190 | 0.83 | CA2 (0.61) | CA2CYP1A2CYP3A4CYP2D6ATM | |
| SCHEMBL11269213 | 0.82 | SMN1; SMN2 (0.57) | CA2ALDH1A1LDHAMAPT | |
| SCHEMBL11265685 | 0.82 | CYP1A2 (0.61) | CA2CYP1A2ALDH1A1LDHAMAPT | |
| SCHEMBL28482410 | 0.82 | TAAR1 (0.62) | CYP3A4ALDH1A1GAATDP1 | |
| SCHEMBL28509106 | 0.81 | MEN1 (0.63) | CYP1A2CYP3A4CYP2D6KDM4EBLM | |
| SCHEMBL16641094 | 0.79 | CYP19A1 (0.77) | CA2CYP1A2CYP3A4CYP2D6ATM | |
| SCHEMBL31157848 | 0.79 | CYP19A1 (0.77) | CA2CYP1A2CYP3A4CYP2D6ATM | |
| SCHEMBL2095593 | 0.79 | CA2 (1.00) | CA2CYP1A2CYP3A4CYP2D6ATM | |
| SCHEMBL11444350 | 0.79 | CA2 (0.55) | CA2CYP1A2CYP3A4CYP2D6ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013083541-A1 | (4-MERCAPTO-PIPERIDIN-4-YL)-AMINOACETIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | LACER, S.A. (ES) | 2013-06-13 | — | — | WO | disclosed |
| EP-2601940-A1 | (4-mercapto-piperidin-4-yl)-aminoacetic acid derivatives, pharmaceutical compositions and uses thereof | LACER, S.A. (ES) | 2013-06-12 | — | — | EP | disclosed |
| EP-2125727-B1 | STABLE S-NITROSOTHIOLS, METHOD OF SYNTHESIS AND USE | LACER SA (ES) | 2012-11-21 | — | — | EP | disclosed |
| CN-101600692-B | Stable s-nitrosothiols, method of synthesis and use | LACER SA ES | 2012-07-04 | — | — | CN | disclosed |
| US-8012993-B2 | e.g. ethyl(R,S)-acetylamino-(1-methyl-4-S-nitrosomercapto-piperidin-4-yl)-acetate; vasodilating effect which inhibit the aggregation of the platelets; hypotensive agent, vasodilator; thrombosis, graft rejections, ischemia-reperfusion; adding mercaptan compound to heterocyclic followed by nitrosation | LACER, S.A. (ES) | 2011-09-06 | — | — | US | disclosed |
| CN-101600692-A | Stable S-nitrosothiol, preparation method and use | LACER SA (ES) | 2009-12-09 | — | — | CN | disclosed |
| EP-2125727-A1 | STABLE S-NITROSOTHIOLS, METHOD OF SYNTHESIS AND USE | LACER, S.A. (ES) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008080986-A1 | FURAN DERIVATIVES, METHOD OF SYNTHESIS AND USES THEREOF | NEUROPHARMA, S.A. (ES) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008080934-A1 | STABLE S-NITROSOTHIOLS, METHOD OF SYNTHESIS AND USE | LÁCER, S.A. (ES) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161354-A1 | STABLE S-NITROSOTHIOLS, METHOD OF SYNTHESIS AND USE | LACER, S.A. (ES) | 2008-07-03 | — | — | US | disclosed |
| EP-1939179-A1 | Stable S-nitrosothiols, method of synthesis and use | LACER, S.A. (ES) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939191-A1 | Furan derivatives, method of synthesis and uses thereof | Neuropharma S.A. (ES) | 2008-07-02 | — | — | EP | disclosed |
| US-4120866-A | REACTING AN AROMATIC COMPOUND WITH A SULFOXIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1978-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161354-A1 | STABLE S-NITROSOTHIOLS, METHOD OF SYNTHESIS AND USE | NOS2, PTGIS, NOS1 | CA2 2151/4885CYP1A2 204/4885CYP3A4 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.